2.66 (-%)
As of Nov 20, 2024
Source:
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Our initial focus is on advancing AV-101, our dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, or PAH, a devastating disease impacting approximately 70,000 people in the United States and Europe.
Country | United States |
Headquarters | waltham, massachusetts |
Phone Number | 617-443-2400 |
Industry | |
CEO | Timothy P. Noyes |
Website | www.aerovatetx.com |